1. LB0005 12-week results of a phase 2B dose-ranging study of LY3009104 (INCB028050), an oral JAK1/JAK2 inhibitor, in combination with traditional dmards in patients with rheumatoid arthritis. (23rd January 2014) Authors: Keystone, E.; Taylor, P.; Genovese, M.; Schlichting, D.; Beattie, S.; Gaich, C.; Fidelus Gort, R.; Luchi, M.; Macias, W.L. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗